Pfizer Inc. (NYSE:PFE) Shares Sold by GeoWealth Management LLC

GeoWealth Management LLC cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 40.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,763 shares of the biopharmaceutical company's stock after selling 13,981 shares during the period. GeoWealth Management LLC's holdings in Pfizer were worth $551,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in PFE. Passumpsic Savings Bank increased its position in shares of Pfizer by 8.4% during the 3rd quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock valued at $743,000 after purchasing an additional 1,998 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Pfizer during the 3rd quarter worth about $1,499,000. Westside Investment Management Inc. raised its position in Pfizer by 7.7% in the 3rd quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock worth $404,000 after purchasing an additional 1,004 shares during the period. Diamant Asset Management Inc. boosted its position in shares of Pfizer by 8.4% during the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock valued at $246,000 after buying an additional 660 shares during the period. Finally, Morse Asset Management Inc bought a new stake in shares of Pfizer during the 3rd quarter worth approximately $2,649,000. Institutional investors own 68.36% of the company's stock.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on PFE shares. UBS Group decreased their target price on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research report on Tuesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $31.07.

Pfizer Stock Down 0.3 %

NYSE:PFE traded down $0.07 during midday trading on Monday, reaching $22.07. 31,814,050 shares of the stock traded hands, compared to its average volume of 40,452,372. The business has a 50-day moving average of $24.81 and a two-hundred day moving average of $26.11. The stock has a market capitalization of $125.17 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the business posted $0.10 earnings per share. The firm's revenue was up 24.7% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.